

NNDSS Modernization Initiative Technical Assistance Coordination Team Update

February 27, 2015

Colleagues,

Please find below the National Notifiable Diseases Surveillance System (NNDSS) Modernization Initiative (NMI) Technical Assistance (TA) Coordination Team Update for February 27, 2015. These e-mail updates are a collaboration among the Centers for Disease Control and Prevention (CDC), Council of State and Territorial Epidemiologists (CSTE), and the Association of Public Health Laboratories (APHL) and will be sent biweekly in an effort to keep reporting jurisdictions and other partners and stakeholders updated on the progress of NMI.

For more information on NMI, please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.

Message Mapping Guide Development Updates

- The “Methods for Conveying Unknown or Missing Values in Case Notification Messages” document
 - has received final CDC approval and
 - is expected to be posted on the [Draft MMG Web site](#) by the end of February 2015.
- **Message Mapping Guide (MMG) Status Updates:**
 - **Mumps and Pertussis MMGs ([Stage I—Draft Phase](#)):**
 - The MMG Development Team has incorporated unknown/missing indicators and revised the Mumps and Pertussis MMGs to reflect the new HL7 message structure.
 - The team expects to post the revised guides in March 2015 for a second external review period of approximately 4 weeks.
 - **Congenital Syphilis and STD MMGs ([Stage II—Reconciled Draft Phase](#))**
 - The MMG Development Team has incorporated unknown/missing indicators and revised the STD and Congenital Syphilis MMGs to reflect the new HL7 message structure.
 - The team delivered the restructured STD MMG, test messages, and test scenarios to the Message Validation, Processing, and Provisioning (MVPS) Team in February 2015.
 - The MMG Development Team delivered the restructured Congenital Syphilis MMG to the MVPS Team on 2/13/2015 and is now updating the test messages and test scenarios, expected to be delivered to the MVPS Team by the end of February 2015.
 - The MMG Development Team will post the STD and Congenital Syphilis MMGs as soon as possible as [Stage III—Pilot Test-ready Draft Phase](#) versions of the MMGs, along with their artifacts.

- **Generic v2 and Hepatitis MMGs** ([Stage III—Pilot Test-ready Draft Phase](#))
 - The MMG Development Team has revised the Generic v2 MMG, test scenarios, and test messages to reflect the new HL7 message structure (incorporating core lab and vaccine variables).
 - The team has incorporated unknown/missing indicators and revised the Hepatitis MMG, test scenarios, and test messages to reflect the new HL7 message structure.
 - The team delivered the restructured Generic v2 and Hepatitis MMGs, test messages, and test scenarios to the MVPS Team in February 2015.
 - The MMG Development Team expects to post updated versions of the Generic v2 and Hepatitis artifacts to the Draft MMG Web site in February 2015.
- No guides are in [Stage IV—Final MMG Phase](#) at this time.

Message Validation, Processing, and Provisioning System Updates

- The MVPS Team is supporting the documentation and clarification of the MVPS system requirements as follows:
 - In February 2015, the MVPS Team submitted to AgileX the finalized role-based dashboard security requirements, which incorporated all clarifications from ongoing discussions with AgileX and updated the documentation delivered to AgileX at the end of January.
 - In addition, the team delivered to AgileX the week of 2/17/2015 the final dashboard submission, which includes an interactive mockup of the MVPS Quality Control (QC) Dashboard that incorporates system roles and overall dashboard functionality requirements. The MVPS team and AgileX have scheduled a meeting for 2/26/2015 to conduct the final review and clarification activities.
 - On 2/17/2015, the MVPS Team submitted to AgileX the message restructuring functional requirements in support of Gen v2, Hepatitis, and STD, including the new Public Health Information Network (PHIN) Specification and Gen v2, Hepatitis, and STD MMGs. The MVPS Team and AgileX are now reviewing and clarifying the documents.
- The MVPS Team continues to support the new MMG message restructuring effort:
 - The MVPS Team continues to work on the message restructuring requirements documents for Congenital Syphilis and expects to finalize them by early March 2015.
 - When the message restructuring is completed, MVPS and the Message Evaluation and Testing Service (METS) tool will be updated to reflect the new message structure and associated processing changes for the four disease types (Gen v2, Hepatitis, STD, Congenital Syphilis). System functionality in support of validation testing with the jurisdictions is expected to be available in June 2015.

Technical Assistance Updates

- Given the updated scope and timeline for NMI, the NMI Technical Assistance (TA) Coordination Team has held conference calls with potential pilot jurisdictions to reassess their continued interest and readiness to participate in and receive TA between March and June 2015.
- The team has planned the “NMI TA Pilot Project Phase II: Orientation for Pilot Jurisdictions” webinar to be held on 2/27/2015.

- During the webinar, the team will provide an update on the status of NMI, including refinements made during the first 6 months of the project; clarify expectations and share information to help jurisdictions prepare to implement the new case notification messages, including lessons learned from Michigan; and review the revised timeline for NMI for non-National Electronic Disease Surveillance System Base System (NBS) states.
- The team has developed tools, resources, and trainings—such as the MMG implementation template, integration broker mappers, and other technical assistance training materials—that will be discussed with NMI pilot jurisdictions during the webinar.
- NMI will be the topic of the 3/4/2015 Public Health Information Network (PHIN) Partner Call. On this call, NMI leadership will provide an update on the status of NMI, including refinements made during the initial 6 months of the project; share information on the development of tools and resources to help jurisdictions to prepare to implement the new case notification messages; and review the current timeline for NMI.
- Reminder about MMG status:
 - MMGs in Stages I, II, and III are considered draft and may be revised until the time they are finalized.
 - Those jurisdictions selected for pilot testing of the test-ready versions (Stage III) of the MMGs should wait until contacted by the NMI TA Team before using the test-ready MMGs, before implementing surveillance information system changes, and before submitting test messages to CDC.
 - All other jurisdictions should not plan to submit data to CDC or implement MMG-based updates to their surveillance information systems until the final MMGs (Stage IV) have been posted to the PHIN website.
- For more information about technical assistance:
 - Please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>.
 - For pilot jurisdictions: If you have questions specific to NMI TA, please contact Laura Carlton, contractor to APHL, at lcarlton@TSJG.com.
 - For non-pilot jurisdictions: If you have questions or would like to request TA for MMG implementation through the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Cooperative Agreement, please email edx@cdc.gov.

For more information on NMI, please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.